11.07

1.25% -0.14

Pre-market: 10.61 -0.46 -4.16%

Pliant Therapeutics Inc (PLRX)

Overview News Price History Option Chain Financials Discussions Forecast

Pliant Therapeutics Inc stock is traded at $11.07, with a volume of 669.57K. It is down -1.25% in the last 24 hours and down -16.20% over the past month. Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Previous Close:

$11.21

Open:

$11.07

24h Volume:

669.57K

Relative Volume:

1.42

Market Cap:

$673.65M

Revenue:

$5.03M

Net Income/Loss:

$-185.41M

P/E Ratio:

-3.5825

EPS:

-3.09

Net Cash Flow:

$-139.79M

1W Performance:

-1.51%

1M Performance:

-16.20%

6M Performance:

-10.44%

1Y Performance:

-33.71%

1-Day Range:

$11.04

$11.40

1-Week Range:

$10.94

$12.70

52-Week Range:

$10.22

$18.92

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name

Pliant Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (685)

Phone

650-481-6770

Address

331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA

Employee

166

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

PLRX's Discussions on Twitter

Compare PLRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PLRX Pliant Therapeutics Inc	11.07	673.65M	5.03M	-185.41M	-139.79M	-3.09
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-09-24	Resumed	Leerink Partners	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
May-18-23	Initiated	Canaccord Genuity	Buy
Apr-13-23	Initiated	Robert W. Baird	Outperform
Dec-14-22	Initiated	Stifel	Buy
Dec-07-22	Initiated	JP Morgan	Overweight
Sep-01-22	Initiated	Citigroup	Buy
Jul-20-22	Initiated	SVB Leerink	Outperform
May-25-22	Initiated	Cantor Fitzgerald	Overweight
Dec-10-21	Initiated	Oppenheimer	Outperform
Nov-24-21	Initiated	RBC Capital Mkts	Outperform
Nov-03-21	Initiated	H.C. Wainwright	Buy
Apr-20-21	Initiated	BTIG Research	Buy
Apr-05-21	Initiated	Citigroup	Buy
Jun-29-20	Initiated	Citigroup	Buy
Jun-29-20	Initiated	Cowen	Outperform
Jun-29-20	Initiated	Needham	Buy
Jun-29-20	Initiated	Piper Sandler	Overweight

View All

Pliant Therapeutics Inc Stock (PLRX) Latest News

Jan 21, 2025

Pliant Therapeutics (NASDAQ:PLRX) versus EOM Pharmaceuticals (OTCMKTS:IMUC) Head to Head Analysis - Defense World

Jan 21, 2025

Jan 19, 2025

PLRX (Pliant Therapeutics) 3-Year EPS without NRI Growth Ra - GuruFocus.com

Jan 19, 2025

Jan 18, 2025

PLRX (Pliant Therapeutics) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2024) - GuruFocus.com

Jan 18, 2025

Jan 17, 2025

Pliant Therapeutics (NASDAQ:PLRX) Shares Down 5.2%Here's Why - MarketBeat

Jan 17, 2025

Learn to Evaluate (PLRX) using the Charts - Stock Traders Daily

Jan 17, 2025

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Jan 17, 2025

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Jan 17, 2025

Jan 15, 2025

Pliant Therapeutics (NASDAQ:PLRX) Stock Price Up 11%Still a Buy? - MarketBeat

Jan 15, 2025

Jan 02, 2025

Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 02, 2025

Pliant Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 02, 2025

Pliant Therapeutics (NASDAQ:PLRX) Has Debt But No Earnings; Should You Worry? - Simply Wall St

Jan 02, 2025

Dec 31, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock Position Boosted by Geode Capital Management LLC - Defense World

Dec 31, 2024

Dec 30, 2024

Pliant Therapeutics (NASDAQ:PLRX) Trading Down 4.9%Time to Sell? - MarketBeat

Dec 30, 2024

Dec 29, 2024

Contrasting Pliant Therapeutics (NASDAQ:PLRX) & Bionomics (NASDAQ:BNOX) - Defense World

Dec 29, 2024

Dec 27, 2024

When (PLRX) Moves Investors should Listen - Stock Traders Daily

Dec 27, 2024

Dec 25, 2024

State Street Corp Raises Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Dec 25, 2024

Dec 23, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Rating of “Buy” from Brokerages - Defense World

Dec 23, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $40.50 Consensus Price Target from Analysts - MarketBeat

Dec 23, 2024

Dec 20, 2024